Investigational Combination Immunotherapy

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

       
  Multikine Investigational Therapy  
       

While active and passive immunotherapies respectively mimic some parts of our immune system, available evidence suggests that combination immunotherapy has the potential to most closely resemble the workings of the natural immune system. This type of immunotherapy is thought to work on multiple fronts against advanced primary head and neck cancer.  Combination immunotherapy:

  o Is thought to have the potential to cause a direct effect on the tumor cells  
       
  o Is thought to have the potential to activate the immune system to produce an anti-tumor immune response  

Combination immunotherapy has the potential to activate multiple cellular components of the immune system which may cause an anti-tumor immune response.

Multikine Investigational Therapy: A Potential Combination Immunotherapy in what may become a new class of immunotherapy drugs

Multikine is an investigational new drug being studied as a potential combination immunotherapy for the potential treatment of advanced primary head and neck cancer.  Histopathology studies conducted on clinical specimens collected during Phase II clinical trials indicate that this investigational therapy possibly could directly affect tumor cells and potentially activate an anti-tumor immune response.  No definitive conclusions can be drawn from these data about the potential efficacy or safety profile of this investigational therapy, and further research is required and a Phase III clinical study is ongoing in an effort to confirm these results.

Preliminary data from early-phase clinical studies on the Multikine investigational therapy suggest that it may have the potential to act on multiple fronts:

  o It is thought to have the potential to act on the cancer cell  
       
  o It is thought to have the potential to cause a direct effect on the tumor cells  
       
  o It is thought to have the potential to activate the immune system to produce an anti-tumor immune response  
       
  o It is thought to have the potential to possibly render residual tumor cells more susceptible to radiation and/or chemotherapy  

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.